Published in N Engl J Med on May 25, 1995
Cost effectiveness analysis in health care: contraindications. BMJ (2002) 1.80
Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting. BMJ (2011) 1.59
The limited incorporation of economic analyses in clinical practice guidelines. J Gen Intern Med (2002) 1.10
Prostate cancer: 2. Natural history. CMAJ (1998) 1.06
Years-needed-to-treat to add 1 year of life: a new metric to estimate treatment effects in randomized trials. Eur J Heart Fail (2009) 1.03
Assessing the effectiveness of health interventions for cost-effectiveness analysis. Panel on Cost-Effectiveness in Health and Medicine. J Gen Intern Med (1997) 1.00
A catalytic switch and the conversion of streptokinase to a fibrin-targeted plasminogen activator. Proc Natl Acad Sci U S A (1999) 0.97
Individualized cost-effectiveness analysis. PLoS Med (2011) 0.92
An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study. Clinicoecon Outcomes Res (2013) 0.91
The economic case for new stroke thrombolytics. Stroke (2010) 0.86
Single nucleotide polymorphism discovery and haplotype analysis of Ca2+-dependent K+ channel beta-1 subunit. Pharmacogenet Genomics (2007) 0.85
Translating research evidence into clinical practice: new challenges for critical care. Crit Care (2002) 0.84
Primary Angioplasty for the Treatment of Acute ST-Segment Elevated Myocardial Infarction: An Evidence-Based Analysis. Ont Health Technol Assess Ser (2004) 0.79
A generalised model for individualising a treatment recommendation based on group-level evidence from randomised clinical trials. BMJ Open (2013) 0.78
Economic evaluation of treating clinically isolated syndrome and subsequent multiple sclerosis with interferon beta-1b. Neurol Sci (2009) 0.78
Is the use of t-PA as compared with streptokinase cost effective? N Engl J Med (1995) 0.77
Economic evaluation of adolescent addiction programs: methodologic challenges and recommendations. J Adolesc Health (2008) 0.75
How to assess an article on economic evaluation. Sex Transm Infect (1998) 0.75
Prophylactic replacement of Bjŏrk-Shiley convexo-concave heart valves: an easy-to-use tool to aid decision-making in individual patients. Heart (1997) 0.75
Is thrombolytic therapy really better than conventional treatment in acute inferior myocardial infarction? Br Heart J (1995) 0.75
Applying the results of large clinical trials in the management of acute myocardial infarction. West J Med (1996) 0.75
Debate: Should the elderly receive thrombolytic therapy, or primary angioplasty, for acute myocardial infarction? The case for primary angioplasty. Curr Control Trials Cardiovasc Med (2000) 0.75
Cost effectiveness of tissue plasminogen activator. N Engl J Med (1995) 0.75
Decision-analytic valuation of clinical information systems: application to an alerting system for coronary angiography. Proc AMIA Annu Fall Symp (1997) 0.75
Using models to predict the future: what to do when the data run out? Clin Pharmacol Ther (2012) 0.75
Assessing the value of newer pharmacologic agents in non-ST elevation patients: a decision support system application. Proc AMIA Annu Fall Symp (1997) 0.75
Is the use of t-PA as compared with streptokinase cost effective? N Engl J Med (1995) 0.75
Vancomycin flush as antibiotic prophylaxis for early catheter-related infections: a cost-effectiveness analysis. Support Care Cancer (2008) 0.75
Understanding the Value of Individualized Information: The Impact of Poor Calibration or Discrimination in Outcome Prediction Models. Med Decis Making (2017) 0.75
Biases in Individualized Cost-effectiveness Analysis: Influence of Choices in Modeling Short-Term, Trial-Based, Mortality Risk Reduction and Post-Trial Life Expectancy. Med Decis Making (2017) 0.75
Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med (1996) 46.18
The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators. JAMA (1996) 17.62
Evaluating the yield of medical tests. JAMA (1982) 14.05
An amino acid liquid synthetic medium for the development of mycelial and yeast forms of Candida Albicans. Sabouraudia (1975) 11.53
A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med (1999) 10.17
Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet (1996) 8.50
Clinical judgment and statistics. Lessons from a simulated randomized trial in coronary artery disease. Circulation (1980) 7.96
Effects of socioeconomic status on access to invasive cardiac procedures and on mortality after acute myocardial infarction. N Engl J Med (1999) 7.68
Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med (2011) 7.62
Regression modelling strategies for improved prognostic prediction. Stat Med (1984) 7.09
Use of medical resources and quality of life after acute myocardial infarction in Canada and the United States. N Engl J Med (1994) 6.78
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med (1997) 6.19
Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med (1996) 5.94
Users' guides to the medical literature: XXII: how to use articles about clinical decision rules. Evidence-Based Medicine Working Group. JAMA (2000) 5.94
Racial variation in the use of coronary-revascularization procedures. Are the differences real? Do they matter? N Engl J Med (1997) 5.80
Randomised trials of secondary prevention programmes in coronary heart disease: systematic review. BMJ (2001) 5.63
Value of the history and physical in identifying patients at increased risk for coronary artery disease. Ann Intern Med (1993) 5.59
Outcome of acute myocardial infarction according to the specialty of the admitting physician. N Engl J Med (1996) 5.51
A brief self-administered questionnaire to determine functional capacity (the Duke Activity Status Index). Am J Cardiol (1989) 5.50
A systematic review of randomized trials of disease management programs in heart failure. Am J Med (2001) 5.38
Users' guides to the medical literature. XII. How to use articles about health-related quality of life. Evidence-Based Medicine Working Group. JAMA (1997) 5.07
Incorporating variations in the quality of individual randomized trials into meta-analysis. J Clin Epidemiol (1992) 4.86
Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med (2001) 4.85
Use of cardiac procedures and outcomes in elderly patients with myocardial infarction in the United States and Canada. N Engl J Med (1997) 4.84
Role of the accessory gene regulator (agr) in pathogenesis of staphylococcal osteomyelitis. Infect Immun (1995) 4.58
How should health status measures be assessed? Cautionary notes on procrustean frameworks. J Clin Epidemiol (1992) 4.54
Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators. N Engl J Med (1999) 4.53
Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet (1999) 4.36
Regional variation across the United States in the management of acute myocardial infarction. GUSTO-1 Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. N Engl J Med (1995) 4.29
Logistic regression in the medical literature: standards for use and reporting, with particular attention to one medical domain. J Clin Epidemiol (2001) 4.20
Cost effectiveness of early discharge after uncomplicated acute myocardial infarction. N Engl J Med (2000) 4.19
1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol (1999) 4.15
Regression models in clinical studies: determining relationships between predictors and response. J Natl Cancer Inst (1988) 4.07
Meta-analysis and the meta-epidemiology of clinical research. BMJ (1997) 4.07
Do we know what inappropriate laboratory utilization is? A systematic review of laboratory clinical audits. JAMA (1998) 3.96
Prognostic value of a treadmill exercise score in outpatients with suspected coronary artery disease. N Engl J Med (1991) 3.63
Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation (2000) 3.61
Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med (1993) 3.53
Referral patterns for coronary artery disease treatment: gender bias or good clinical judgment? Ann Intern Med (1992) 3.39
Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. Circulation (1995) 3.38
Scorecard cardiovascular medicine. Its impact and future directions. Ann Intern Med (1994) 3.32
Job strain and the prevalence and outcome of coronary artery disease. Circulation (1995) 3.22
Communicating the benefits of chronic preventive therapy: does the format of efficacy data determine patients' acceptance of treatment? Med Decis Making (1995) 3.21
Improved survival after early thrombolysis in acute myocardial infarction. A randomised trial by the Interuniversity Cardiology Institute in The Netherlands. Lancet (1985) 3.13
Resuscitation preferences among patients with severe congestive heart failure: results from the SUPPORT project. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. Circulation (1998) 3.11
The SUPPORT prognostic model. Objective estimates of survival for seriously ill hospitalized adults. Study to understand prognoses and preferences for outcomes and risks of treatments. Ann Intern Med (1995) 3.08
Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation; recommendations of the Task Force of the European Society of Cardiology. Eur Heart J (2000) 3.07
Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. Circulation (1999) 3.06
Prognostic importance of social and economic resources among medically treated patients with angiographically documented coronary artery disease. JAMA (1992) 3.06
Impact of increasing carbohydrate intolerance on maternal-fetal outcomes in 3637 women without gestational diabetes. The Toronto Tri-Hospital Gestational Diabetes Project. Am J Obstet Gynecol (1995) 3.05
A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med (1987) 3.04
Multicenter validation of a risk index for mortality, intensive care unit stay, and overall hospital length of stay after cardiac surgery. Steering Committee of the Provincial Adult Cardiac Care Network of Ontario. Circulation (1995) 3.02
Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty. Lancet (1988) 2.90
Clinical data bases. Accomplishments and unrealized potential. Med Care (1985) 2.83
Determinants of the use of coronary angiography and revascularization after thrombolysis for acute myocardial infarction. N Engl J Med (1996) 2.83
ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol (1996) 2.81
Difference in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: results from the GUSTO trial. Lancet (1997) 2.80
Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med (2000) 2.80
Regression models for prognostic prediction: advantages, problems, and suggested solutions. Cancer Treat Rep (1985) 2.76
Variation in breast cancer surgery in Ontario. CMAJ (1994) 2.70
Association of revascularisation with low mortality in non-ST elevation acute coronary syndrome, a report from GUSTO IV-ACS. Eur Heart J (2004) 2.67
Ready-made, recalibrated, or Remodeled? Issues in the use of risk indexes for assessing mortality after coronary artery bypass graft surgery. Circulation (1999) 2.67